Cite
HARVARD Citation
Cai, W. et al. (2021). Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action. Antibody therapeutics. pp. 228-241. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Cai, W. et al. (2021). Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action. Antibody therapeutics. pp. 228-241. [Online].